Detailed Information

Cited 28 time in webofscience Cited 32 time in scopus
Metadata Downloads

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

Authors
Vissing, JohnJacob, SaijuFujita, Kenji P.O’Brien, FannyHoward, James F.Mazia, C.G.Wilken, M.Barroso, F.Saba, J.Rugiero, M.Bettini, M.Chaves, M.Vidal, G.Garcia, A.D.De Bleecker, J.Van den, Abeele G.de Koning, K.De Mey, K.Mercelis, R.Mahieu, D.Wagemaekers, L.Van Damme, P.Depreitere, A.Schotte, C.Smetcoren, C.Stevens, O.Van Daele, S.Vandenbussche, N.Vanhee, A.Verjans, S.Vynckier, J.D’Hont, A.Tilkin, P.Alves, de Siqueira Carvalho A.Dias Brockhausen, I.Feder, D.Ambrosio, D.César, P.Melo, A.P.Martins Ribeiro, R.Rocha, R.Rosa, B.B.Veiga, T.da Silva, L.A.Santos Engel, M.Gonçalves Geraldo, J.da Penha, Ananias Morita M.Nogueira Coelho, E.Paiva, G.Pozo, M.Prando, N.Martineli Torres, D.D.Butinhao, C.F.Duran, G.Suriane Fialho, T.A.Gomes, da Silva T.C.Maia Gonçalves, L.O.Pazetto, L.E.Cubas Volpe, L.R.Souza Duca, L.Gheller Friedrich, M.A.Guerreiro, A.Mohr, H.Pereira Martins, M.da Cruz, Pacheco D.Ferreira, L.Macagnan, A.P.Pinto, G.de Cassia, Santos A.Souza, Bulle Oliveira A.Amaral, de Andrade A.C.Annes, M.Duarte Silva, L.Cavalcante Lino, V.Pinto, W.Assis, N.Carrara, F.Miranda, C.Souza, I.Fernandes, P.Siddiqi, Z.Phan, C.Narayan, J.Blackmore, D.Mallon, A.Roderus, R.Watt, E.Vohanka, S.Bednarik, J.Chmelikova, M.Cierny, M.Toncrova, S.Junkerova, Barbora Kurkova J.Reguliova, K.Zapletalova, O.Pitha, J.Novakova, I.Tyblova, M.Jurajdova, I.Wolfova, M.Andersen, H.Harbo, T.Vinge, L.Krogh, S.Mogensen, A.Vissing, J.Højgaard, J.Witting, N.Mette, Ostergaard Autzen A.Pedersen, J.Erälinna, J.-P.Laaksonen, M.Oksaranta, O.Harrison, T.Eriksson, J.Rozsa, C.Horvath, M.Lovas, G.Matolcsi, J.Szabo, G.Jakab, G.Szabadosne, B.Vecsei, L.Dezsi, L.Varga, E.Konyane, M.Antonini, G.Di Pasquale, A.Garibaldi, M.Morino, S.Troili, F.Fionda, L.Saccà, F.previous,Filla, A.sub-investigators,Costabile, T.Marano, E.Fasanaro, A.Marsili, A.Puorro, G.Mantegazza, R.Antozzi, C.Bonanno, S.Camera, G.Locatelli, A.Maggi, L.Pasanisi, M.Campanella, A.Evoli, A.Alboini, P.E.D’Amato, V.Iorio, R.Inghilleri, M.Fionda, L.Frasca, V.Giacomelli, E.Gori, M.Lopergolo, D.Onesti, E.Frasca, V.Gabriele, M.Uzawa, A.Kanai, T.Kawaguchi, N.Mori, M.Kaneko, Y.Kanzaki, A.Kobayashi, E.Murai, H.Masaki, K.Matsuse, D.Matsushita, T.Uehara, T.Shimpo, M.Jingu, M.Kikutake, K.Nakamura, Y.Sano, Y.Utsugisawa, K.Nagane, Y.Kamegamori, I.Tsuda, T.Fujii, Y.Futono, K.Ozawa, Y.Mizugami, A.Saito, Y.Samukawa, M.Suzuki, H.Morikawa, M.Kamakura, S.Miyawaki, E.Shiraishi, H.Mitazaki, T.Motomura, M.Mukaino, A.Yoshimura, S.Asada, S.Yoshida, S.Amamoto, S.Kobashikawa, T.Koga, M.Maeda, Y.Takada, K.Takada, M.Tsurumaru, M.Yamashita, Y.Yoshida, S.Suzuki, Y.Akiyama, T.Narikawa, K.Tano, O.Tsukita, K.Kurihara, R.Meguro, F.Fukuda, Y.Sato, M.Okumura, M.Funaka, S.Kawamura, T.Makamori, M.Takahashi, M.Taichi, N.Hasuike, T.Higuchi, E.Kobayashi, H.Osakada, K.Imai, T.Tsuda, E.previous,Shimohama, S.Hayashi, T.Hisahara, S.Imai, T.Kawamata, J.Murahara, T.Saitoh, M.Shimohama, S.Suzuki, S.Yamamoto, D.Ishiyama, Y.Ishiyama, N.Noshiro, M.Takeyama, R.Uwasa, K.Yasuda, I.Kim, Byung-JoLee, C.N.Koo, Y.S.Seok, H.Y.Kang, H.N.Ra, H.J.Kim, B.J.Cho, E.B.Choi, M.S.Lee, H.L.Min, J.-H.Seok, J.Lee, J.E.Koh, D.Y.Kwon, J.Y.Park, S.A.Choi, E.H.Hong, Y.-H.Ahn, S.-H.Koo, D.L.Lim, J.-S.Shin, C.W.Hwang, J.Y.Kim, M.Kim, S.M.Jeong, H.-N.Jung, J.W.Kim, Y.-H.Lee, H.S.Shin, H.Y.Hwang, E.B.Shin, M.van, der Kooi A.de Visser, M.Gibson, T.Casasnovas, C.Alberti Aguilo, M.A.Homedes-Pedret, C.Palacios, N.J.Diez Porras, L.Velez Santamaria, V.Lazaro, A.Diez Tejedor, E.Gomez Salcedo, P.Fernandez-Fournier, M.Lopez Ruiz, P.Rodriguez, de Rivera F.J.Fernandez-Fournier, M.Sastre, M.Gamez Carbonell, J.Sune, P.Salvado Figueras, M.Gili, G.Mazuela, G.Illa, I.Cortes Vicente, E.Diaz-Manera, J.Querol Gutiérrez, L.A.Rojas Garcia, R.Vidal, N.Arribas-Ibar, E.Piehl, F.Hietala, A.Bjarbo, L.Sengun, I.Meherremova, A.Ozcelik, P.Balkan, B.Tuga, C.Ugur, M.Erdem-Ozdamar, S.Bekircan-Kurt, C.E.Acar, N.P.Yilmaz, E.Caliskan, Y.Orsel, G.Efendi, H.Aydinlik, S.Cavus, H.Kutlu, A.Becerikli, G.Semiz, C.Tun, O.Terzi, M.Dogan, B.Onar, M.K.Sen, S.Kirbas Cavdar, T.Veske, A.Norwood, F.Dimitriou, A.Gollogly, J.Mahdi-Rogers, M.Seddigh, A.Sokratous, G.Maier, G.Sohail, F.Sadalage, G.Torane, P.Brown, C.Shah, A.Sathasivam, S.Arndt, H.Davies, D.Watling, D.Amato, A.Cochrane, T.Salajegheh, M.Roe, K.Amato, K.Toska, S.Wolfe, G.Silvestri, N.Patrick, K.Zakalik, K.Katz, J.Miller, R.Engel, M.Forshew, D.Bravver, E.Brooks, B.Sanjak, M.Plevka, S.Burdette, M.Cunningham, S.Sanjak, M.Kramer, M.Nemeth, J.Schommer, C.Tinerney, S.Juel, V.Guptill, J.Hobson-Webb, L.Massey, J.Beck, K.Carnes, D.Loor, J.Anderson, A.Pascuzzi, R.Bodkin, C.Kincaid, J.Snook, R.Guinrich, S.Micheels, A.Chaudhry, V.Corse, A.Mosmiller, B.Kelley, A.Ho, D.Srinivasan, J.Vytopil, M.Jara, J.Ventura, N.Carter, C.Donahue, C.Herbert, C.Scala, S.Weiner, E.Alam, S.McKinnon, J.Haar, L.McKinnon, N.Alcon, K.McKenna, K.Sattar, N.Daniels, K.Jeffery, D.Freimer, M.Hoyle, J.C.Kissel, J.Agriesti, J.Chelnick, S.Mezache, L.Pineda, C.Muharrem, F.Karam, C.Khoury, J.previous,Marburger, T.Kaur, H.Dimitrova, D.Gilchrist, J.Agrawal, B.Elsayed, M.Kohlrus, S.Andoin, A.Darnell, T.Golden, L.Lokaitis, B.Seelbach, J.Muppidi, S.Goyal, N.Sakamuri, S.So, Y.T.Paulose, S.Pol, S.Welsh, L.Bhavaraju-Sanka, R.Tobon Gonzalez, A.Dishman, L.Jones, F.Gonzalez, A.Padilla, P.Saklad, A.Silva, M.Nations, S.Trivedi, J.Hopkins, S.Kazamel, M.Alsharabati, M.Lu, L.Nozaki, K.Mumfrey-Thomas, S.Woodall, A.Mozaffar, T.Cash, T.Goyal, N.Roy, G.Mathew, V.Maqsood, F.Minton, B.Jones, H.J.Rosenfeld, J.Garcia, R.Echevarria, L.Garcia, S.Pulley, M.Aranke, S.Berger, A.R.Shah, J.Shabbir, Y.Smith, L.Varghese, M.Shabbir, Y.Gutmann, L.Gutmann, L.Jerath, N.Nance, C.Swenson, A.Olalde, H.Kressin, N.Sieren, J.Barohn, R.Dimachkie, M.Glenn, M.McVey, A.Pasnoor, M.Statland, J.Wang, Y.Liu, T.Emmons, K.Jenci, N.Locheke, J.Fondaw, A.Johns, K.Rico, G.Walsh, M.Herbelin, L.Hafer-Macko, C.Kwan, J.Zilliox, L.Callison, K.Young, V.DiSanzo, B.Naunton, K.Benatar, M.Bilsker, M.Sharma, K.Cooley, A.Reyes, E.Michon, S.-C.Sheldon, D.Steele, J.Howard, J.Karam, C.Traub, R.Chopra, M.Vu, T.Katzin, L.McClain, T.Harvey, B.Hart, A.Huynh, K.Beydoun, S.Chilingaryan, A.Doan, V.Droker, B.Gong, H.Karimi, S.Lin, F.McClain, T.Polaka, K.Shah, A.Tran, A.Akhter, S.Malekniazi, A.Tandan, R.Hehir, M.Waheed, W.Lucy, S.Weiss, M.Distad, J.Strom, S.Downing, S.Kim, B.Bertorini, T.Arnold, T.Henderson, K.Pillai, R.Liu, Y.Wheeler, L.Hewlett, J.Vanderhook, M.Nowak, R.Dicapua, D.Keung, B.Kumar, A.Patwa, H.Robeson, K.Yang, I.Nye, J.Vu, H.The, REGAIN study group
Issue Date
Jul-2020
Publisher
Dr. Dietrich Steinkopff Verlag
Keywords
Eculizumab; Refractory; Myasthenia gravis; Minimal symptom expression; Acetylcholine receptor
Citation
Journal of Neurology, v.267, no.7, pp 1991 - 2001
Pages
11
Indexed
SCIE
SCOPUS
Journal Title
Journal of Neurology
Volume
267
Number
7
Start Page
1991
End Page
2001
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/28339
DOI
10.1007/s00415-020-09770-y
ISSN
0340-5354
1432-1459
Abstract
Background The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension. Methods Attainment of ‘minimal symptom expression’ was evaluated using patient-reported outcome measures of gMG symptoms [MG activities of daily living scale (MG-ADL), 15-item MG quality of life questionnaire (MG-QOL15)] at the completion of REGAIN and during the open-label extension. ‘Minimal symptom expression’ was defined as MG-ADL total score of 0–1 or MG-QOL15 total score of 0–3. Results At REGAIN week 26, more eculizumab-treated patients achieved ‘minimal symptom expression’ versus placebo [MG-ADL: 21.4% vs 1.7%; difference 19.8%; 95% confidence interval (CI) 8.5, 31.0; p = 0.0007; MG-QOL15: 16.1% vs 1.7%; difference 14.4%; 95% CI 4.3, 24.6; p = 0.0069]. During the open-label extension, the proportion of patients in the placebo/eculizumab group who achieved ‘minimal symptom expression’ increased after initiating eculizumab treatment and was sustained through 130 weeks of open-label eculizumab (MG-ADL: 1.7 to 27.8%; MG-QOL15: 1.7 to 19.4%). At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved ‘minimal symptom expression’ (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 19.4%, respectively, p = 0.7531). The long-term tolerability of eculizumab was consistent with previous reports. Conclusions Patients with AChR+ refractory gMG who receive eculizumab can achieve sustained ‘minimal symptom expression’ based on patient-reported outcomes. ‘Minimal symptom expression’ may be a useful tool in measuring therapy effectiveness in gMG.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Neurology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Byung-Jo photo

Kim, Byung-Jo
Anam Hospital (Department of Neurology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE